Artificial Intelligence
iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19
NASHUA, N.H., June 01, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm PT. Event registration is available via this link: https://register.gotowebinar.com/register/5960832272590383888.
The roundtable will feature leading specialists in breast cancer treatment, including the following experts*:Charles Wesley Hodge, MD, Radiation Oncologist, Florida Hospital Celebration Health/AdventHealthMichael Howard, PhD, DABMP, RSO, Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA HealthcareSadia Khan, DO, FACS, Assistant Clinical Professor of Surgery at Keck School of Medicine, USC, Director of Integrative Breast Oncology at Hoag Breast ProgramBarry Rosen, MD, FACS, Breast Surgeon, Advocate Healthcare, Managing Partner, TME Breast Care NetworkRakesh Patel, MD (Moderator), Managing Partner, Precision Cancer Specialists, Inc., Managing Partner, Targeted Medical Education (TME) Breast Care Network, Past President, American Brachytherapy Society“The COVID-19 pandemic has introduced unprecedented challenges to our health care system and specifically impacted cancer screenings and treatment in our country and worldwide. During these extraordinary times, it is imperative for clinicians to share best practices and adapt approaches to patient care. iCAD is honored to host virtual events such as this, which provide an educational forum for clinicians to enhance patient care during this global healthcare crisis and beyond,” according to Stacey Stevens, President of iCAD. “In the face of this pandemic, iCAD’s technology is now more relevant than ever. Intraoperative radiation therapy (IORT) with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® offers a viable solution that could potentially alleviate the burden to our health system, while enabling clinicians to administer high-quality care to patients who are candidates, while minimizing their potential exposure to the novel coronavirus.”Xoft breast IORT is a single-fraction therapy option that allows select early-stage breast cancer patients to replace weeks of daily radiation with one treatment, delivered at the time of surgery. This targeted treatment option offers a full course of radiation in just one day, which could contribute to a reduction in the healthcare system resources needed for breast cancer patients during the COVID-19 pandemic and reduce those patients’ risk of exposure to the novel coronavirus by minimizing the number of visits required to a hospital or medical facility.“In the recent months during the COVID-19 pandemic, hospital resources have become limited in many areas, and guidelines issued by a number of medical societies advise clinicians to determine how best to triage the care of cancer patients safely.1 Some breast cancer patients are choosing to delay parts of their treatment for safety concerns,” according to Sadia Khan, DO, FACS, Assistant Clinical Professor of Surgery at Keck School of Medicine, USC, Director of Integrative Breast Oncology at Hoag Breast Program. “In areas where there is still a high incidence of COVID-19, some patients with breast cancer may opt to choose IORT, which offers a one-dose radiation option for patients who meet the criteria. For those who are candidates, IORT gives patients an additional option to complete their radiation in a one-time dose, which decreases their exposure to the hospital.”Positive results from a long-term study involving Xoft breast IORT conducted at Hoag Memorial Hospital Presbyterian were published in the Annals of Surgical Oncology in 2019.2 Led by Melvin J. Silverstein, MD, Medical Director of the Hoag Breast Center, the prospective study, titled Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors, found breast cancer recurrence rates of patients who were treated with Xoft breast IORT were comparable to those seen in the cornerstone, randomized TARGIT-A and ELIOT trials, which evaluated IORT using different technology.“A number of breast cancer patients at our facility have had their treatment delayed due to the COVID-19 pandemic. This is concerning to physicians and patients alike, as some cases could potentially progress and it could result in a considerable backlog of patients who require urgent treatment with more advanced disease,” according to Michael Howard, PhD, DABMP, RSO, Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA Healthcare. “The concern for a second wave of COVID is very real, but IORT offers a way to help reduce this potential backlog.”“The reality is, IORT may be able to play a bigger role right now in the treatment of patients. In some cases, it may be ultimately more beneficial to offer IORT to avoid the backlog in treatment as a means of not overrunning hospitals and radiation centers once we are back up and running,” added Barry Rosen, MD, FACS, Chief of Breast Surgery, Advocate Healthcare and Managing Partner, TME. “IORT is one of those exceptional interventions that I believe satisfies the triple aim in treatment: it offers benefits to patients, providers and payers alike. For patients, it offers added convenience, with better cosmetic outcomes and fewer side effects; from a physician standpoint there is an inherent efficiency, as it enables them to condense one month of daily treatments to a single dose of targeted radiation. Lastly, for payers, the overall cost of treatment is reduced as the course of treatment may be reduced from weeks of daily fractions to one concentrated dose of radiation, administered at the time of surgery.”“As clinicians, we are going to have to adapt to the COVID-19 situation as it evolves. At a certain point, delaying treatment for even early-stage breast cancer is going to come with risk. In many cases, the decision really should be made to go forward with cancer treatment; IORT offers a treatment option that may allow more women to get the treatment they need during this time,” according to Charles Wesley Hodge, MD, Radiation Oncologist, Florida Hospital Celebration Health/AdventHealth. “We are facing an unprecedented challenge in healthcare, and as clinicians we need to come together and adjust to these new realities. For those of us who practice in the oncology space, it is particularly challenging because we are dealing with a potentially life-threatening illness that requires appropriate management. Now is the time for clinicians to work together, to adjust to our new reality, and to come up with an approach that will do the greatest good for our patients.”This virtual roundtable event is a part of larger series of webinars hosted by iCAD in recent weeks, featuring leading experts in breast cancer detection and treatment. This series has examined various aspects of breast cancer care in the era of COVID-19, including risk adaptive tools and pragmatic solutions for both screening and treatment. To view the schedule, register for an upcoming free event, or view a prior event on-demand, visit https://www.icadmed.com/educational-webinars.html.*Panelists have been compensated with an honoraria/speaking fee, but are encouraged to provide their own expert opinions and viewpoints. Dr. Patel is a member of iCAD’s Board of Directors.The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network (NCCN), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology® (ACR®) joint recommendations. “Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic.” https://www.facs.org/-/media/files/quality-programs/napbc/asbrs_napbc_coc_nccn_acr_bc_covid_consortium_recommendations.ashxSilverstein, M.J., Epstein, M., Kim, B. et al. Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors. Ann Surg Oncol 25, 2987–2993 (2018). https://doi.org/10.1245/s10434-018-6614-3. Accessed via https://link.springer.com/article/10.1245/s10434-018-6614-3.About iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.1The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.For more information, visit www.icadmed.com and www.xoftinc.com.Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of IORT to alleviate the burden to our health system and minimize a patient’s potential exposure to Covid-19, to be more beneficial for patients that traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
[email protected]Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
[email protected]
Artificial Intelligence
Astro, Malaysia’s Largest Broadcaster Selects Amagi and AWS to transition Playout Services to the Cloud
KUALA LUMPUR, Malaysia, May 29, 2024 /PRNewswire/ — Amagi, the leader in cloud-based SaaS technology for broadcast and connected TV (CTV), deployed on Amazon Web Services (AWS), today announced its partnership with Malaysia’s leading media and entertainment company – Astro Malaysia Holdings Berhad (Astro).
Astro, Malaysia’s leading content and entertainment company, in partnership with Amagi, is modernizing systems and infrastructure for the playout and origination of its existing Linear Channels and Playout Disaster Recovery capabilities and transitioning them to AWS, the world’s most comprehensive and broadly adopted cloud. This marks a milestone in ASEAN’s broadcast industry. The Amagi playout deployment will help Astro optimize its media operations, enhance business agility, increase service resilience, and mitigate the risks of maintaining legacy systems.
The upcoming launch of the AWS Asia Pacific (Malaysia) Region complements Astro’s ongoing broadcast transformation journey, which aims to further enable the deployment of innovative media and entertainment solutions. By capitalizing on the robust cloud infrastructure, unparalleled scalability, and advanced services provided by AWS, Astro aims to further improve enhanced in-country network infrastructure resiliency and performance, thus delivering enriched customer experiences.
Defining the Future of Broadcast
Broadcasters have traditionally managed their channel automation and playout systems within on-premises data centers. As Astro continues its expansion across multiple regions, the organization will see workflows being optimized, media operations enhanced, and playout system management streamlined. To further complement the company’s pursuit of these goals, Astro will implement Amagi’s flagship products on AWS: the Amagi CLOUDPORT channel playout platform and the Amagi MONITORING solution. These advanced solutions will support Astro’s commitment to operational excellence, offering enhanced resiliency and enabling quicker upgrades to service capabilities, thereby meeting the evolving needs of the broadcasting landscape.
Mauro Di Pietro Paolo, Chief Technology Officer at Astro said, “As Malaysia’s leading broadcaster, Astro continues to drive innovation, and our partnership with Amagi underscores our continuous dedication to pioneering advancements in the industry. At Astro, we needed a playout platform that would align with our vision for transformation in our broadcast and media operations, have in-built disaster recovery capabilities, and provide a modernization path for our end-of-life on-premises systems. We’ve selected Amagi because of their proven track record of deploying playout systems on AWS and have demonstrated their ability to be a transformational platform.”
Srinivasan KA, Co-Founder and Chief Revenue Officer at Amagi said, “We are delighted to partner with Astro, one of the most innovative and forward-looking media companies in Asia, to help them achieve their cloud transformation goals. By leveraging our cloud-native solutions built on AWS’s global infrastructure, we can provide Astro with a scalable, secure, and cost-effective playout platform to support their current and future needs. This collaboration also demonstrates our commitment to empowering media companies with cutting-edge cloud technology and best-in-class service.”
“The broadcast industry is rapidly changing, requiring broadcasters to stay competitive with increased agility, resiliency, cost efficiency, and unified workflows, which can be achieved with AWS cloud. AWS is proud to work with solutions providers like Amagi to drive the industry forward,” said Pete Murray, Country Manager at AWS. “We’re thrilled to see our long-term customer Astro continue its transformative journey to delight their customers, and with Amagi, we look forward to digitalizing and advancing the future of Malaysia’s media and entertainment industry.”
Amagi and Astro launched broadcast station playout origination on AWS for the first channels and disaster recovery services in May 2024. This marks the first large-scale, cloud-based playout solution by a broadcaster in Malaysia. To meet the ever-changing needs of these networks, Amagi will continue to work closely with Astro to scale and evolve its Amagi CLOUDPORT solution.
About Astro
Astro Malaysia Holdings Berhad (Astro) is Malaysia’s leading content and entertainment company, serving 5.3 million homes or 67% of Malaysian TV households, 8,400 enterprises, 18.2 million weekly listeners across FM radio and online, and 15.6 million visitors to our digital brands every month. We serve Malaysians with 3 distinct services – Astro Pay-TV, NJOI Prepaid and sooka, our own OTT for the millennials; and Astro Fibre, our own broadband service, offers greater value with its content-broadband bundles. Close to a million homes are already streaming the best of home entertainment via our Hybrid 4K UHD Ultra Box and HD Ulti Box, which can be self-installed and run on both satellite and broadband. Today, our customers enjoy streaming our local signatures, Astro Originals, live sports and the best global shows from Netflix, Disney+ Hotstar, HBO GO, iQIYI, TVBAnywhere+, beIN SPORTS CONNECT, BBC Player, Viu, ZEE5, WeTV, Qalbox by MuslimPro, and our own TV companion app Astro GO. Astro Radio, home to the country’s highest-rated radio brands across all key languages, and our digital brands including AWANI, SYOK, Gempak, Xuan and Astro Ulagam, connect Malaysians to content and stories that matter.
About Amagi
Amagi is a next-generation media technology company that provides cloud broadcast and targeted advertising solutions to broadcast TV and streaming TV platforms. Amagi enables content owners to launch, distribute, and monetize live linear channels on Free Ad-supported Streaming TV and video services platforms. Amagi also offers 24×7 cloud-managed services bringing simplicity, advanced automation, and transparency to the entire broadcast operations. Overall, Amagi supports 800+ content brands, 800+ playout chains, and over 3800+ channel deliveries on its platform in over 150 countries. Amagi has a presence in New York, Los Angeles, London, Paris, Melbourne, Seoul, Singapore, and broadcast operations in New Delhi, and innovation centers in Bangalore, Zagreb, and Lodz.
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 200 fully-featured services for compute, storage, databases, networking, analytics, machine learning, and AI, Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 102 Availability Zones (AZs) within 32 geographic regions around the world.
In March 2023, AWS announced plans to launch an AWS Infrastructure Region in Malaysia in 2024. As part of its commitment to the region, AWS is planning to invest $6 billion (approx. MYR 25.5 billion) in Malaysia by 2037.
Amagi Contact: Aashish WashikarDirector – Corporate CommunicationsEmail: [email protected] : +91 9533390005
Photo: https://mma.prnewswire.com/media/2423741/Amagi_and_AWS.jpg
View original content:https://www.prnewswire.co.uk/news-releases/astro-malaysias-largest-broadcaster-selects-amagi-and-aws-to-transition-playout-services-to-the-cloud-302157075.html
Artificial Intelligence
The European Patent Office, The world’s most powerful permanent magnet: Japanese inventor selected as finalist for the European Inventor Award 2024
MUNICH, May 29, 2024 /PRNewswire/ — Magnets are all around us, they drive a wide array of modern technologies and exist in one way or another in almost every field on Earth. Permanent neodymium magnets are found nowadays in mobile phones, MRI scanners, electric vehicle motors, wind turbines and security systems as well as in jewellery, ABS brakes, pumps and generators. Their roles go from fastening boxes to helping generate electricity, guiding medical equipment and levitating components. The multifunctional benefits of magnets have changed the way our world works, and Sagawa’s neodymium magnets are a driving force behind the pervasive use of magnets worldwide. In recognition of his achievement, Sagawa is a finalist in the “Non-EPO Countries” category of the European Inventor Award 2024, having been selected by an independent jury from among 550 candidates for this year’s edition.
Motivated by the high price of cobalt at the time and inspired by the widespread availability and lower cost of iron, Sagawa set out in the late 70s and early 80s to find a replacement of cobalt-based magnet, but still be able to generate a robust, permanent magnetic field. He experimented with a wide variety of intermetallic compounds and phases before a breakthrough in the process led him to create the strong magnet. The process he developed is called sintering – a process that bonds the ground particles of his various magnetic components together using heat treatment. While magnets with similar compounds were being developed at the same time, this process made Sagawa’s magnet the strongest in the market.
Masato Sagawa is one of three finalists in the “Non-EPO Countries” category of the European Inventor Award 2024. The other finalists recognised for outstanding work are a Brazilian team led by Fernando Catalano and Micael Carmo for reducing noise and carbon emissions in air travel and American-based David Fattal for his advancements in display optics and software to create glasses-free 3D imaging. The EPO will announce the winners during a ceremony live-streamed here from Malta on 9 July 2024. In addition to each category, the EPO will reveal the Popular Prize winner, chosen by online public vote. Voting will remain open until the day of the ceremony.
Web: https://www.epo.org/en
View original content:https://www.prnewswire.co.uk/news-releases/the-european-patent-office-the-worlds-most-powerful-permanent-magnet-japanese-inventor-selected-as-finalist-for-the-european-inventor-award-2024-302156998.html
Artificial Intelligence
TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON’S DISEASE
– Treefrog will present two posters on their cell therapy program in Parkinson’s Disease and their proprietary encapsulation technology, C-Stem™ –
BORDEAUX, France, May 29, 2024 /PRNewswire/ — TreeFrog Therapeutics has a busy schedule at the ISCT’s 30th annual meeting, taking place in Vancouver, Canada this week, with two posters being presented, one of which has been awarded the Best Poster in the iPSC category. A poster on their transformational encapsulation technology, C-Stem™, will also be presented.
TreeFrog is a cell therapy company with a lead program in Parkinson’s disease, a complex neurodegenerative disease with no cure and treatments that offer symptomatic relief only. Decades of research demonstrate that cell therapy holds immense promise for Parkinson’s disease, with multiple clinical trials ongoing. However, the manufacturing of these cells must overcome major pharmaceutical challenges, including scalability, to be compatible with potential commercial phases. The cell therapy program at TreeFrog is based on C-Stem™, a proprietary technology platform that overcomes these challenges. In 2021, the company achieved a world-first of producing 15billion iPSCs in one run, in one week.
Michael Lanero Fidalgo, Chief Operating Officer, will represent the company for the Best Poster in the iPSC category, an award designed to recognize outstanding abstracts related to iPSC research. Poster #1219, First Off-The-Shelf Bioreactor Produced, iPSC-Derived Neural Microtissues Containing Dopaminergic Neurons Innervate the Striatum and Normalize Behavior in a Parkinson Rat Model, is also one of only twenty posters chosen for an elevator pitch presentation from the overall 600 considered.
Kevin Alessandri, co-founder and Chief Technology Officer, will present poster #1200 Cell encapsulation as a tool for stem cell-based cell therapy industrialization, a deep dive into how the C-Stem™ technology, can overcome the bottlenecks of the complex Chemistry, Manufacturing and Controls (CMC) in cell therapy. He will also participate as a KOL in the JSRM-ISCT iPSC workshop event iPSCs: From Bench to Bedside’ Scientific Signature Series.
Events:
Elevator Pitch presentation by Michael Lanero-Fidalgo, representing lead authors Nicolas Prudon & Lucia Cordero Espinoza May 29th, 2024 @ 12:00 – 13:00, Room 201iPSC Poster Presentation Networking reception (Posters #1219 & #1200) May 30th @ 18:00 – 19:30 Exhibit & Poster HalliPSC: Bench to Bedside: Scientific Signature Series, participation of Kevin Alessandri as KOL. June 1st, 2024 @ 7:30 – 16:00, Room 212-214www.treefrog.fr
CONTACT: Rachel MooneyChief Communications OfficerTreeFrog Therapeutics [email protected]
Logo – https://mma.prnewswire.com/media/2272329/treefrog_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/treefrog-therapeutics-picks-up-best-poster-award-at-the-international-society-for-cell–gene-therapy-isct-annual-meeting-for-their-cell-therapy-program-in-parkinsons-disease-302156935.html
-
Artificial Intelligence5 days agoTitans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Artificial Intelligence5 days agoBybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Artificial Intelligence7 days agoHONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Uncategorized5 days agoGienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized5 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence5 days agoIoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence4 days agoOverseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence5 days agoNorthern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
